Stock Scorer

Lyell Immunopharma, Inc. (LYEL)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. Every figure as a table ›

Revenue Quarterly

0 20M 40M 60M Q3 '21: 2.8M Q4 '21: 2.8M Q1 '22: 553K Q2 '22: 35.7M Q3 '22: 3K Q4 '22: 48.4M Q1 '23: 65K Q2 '23: 27K Q3 '23: 25K Q4 '23: 13K Q1 '24: 3K Q2 '24: 13K Q3 '24: 34K Q4 '24: 11K Q1 '25: 7K Q2 '25: 8K Q3 '25: 15K Q4 '25: 6K Q1 '26: 2K Q2 '26: 4K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Income Quarterly

-210M -140M -70M 0 70M 140M 210M Q3 '21: -49.2M Q4 '21: -47.5M Q1 '22: -68.6M Q2 '22: -37.3M Q3 '22: -66.4M Q4 '22: -14.8M Q1 '23: -62.6M Q2 '23: -65.9M Q3 '23: -59M Q4 '23: -59.5M Q1 '24: -55.6M Q2 '24: -51.5M Q3 '24: -50.5M Q4 '24: -201.1M Q1 '25: -57.4M Q2 '25: -47.1M Q3 '25: -37.3M Q4 '25: -127.6M Q1 '26: -44.3M Q2 '26: -47.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-210M -140M -70M 0 70M 140M 210M Q3 '21: -48.9M Q4 '21: -83.7M Q1 '22: -68.1M Q2 '22: -36.3M Q3 '22: -70.3M Q4 '22: -8.4M Q1 '23: -67M Q2 '23: -63.9M Q3 '23: -50.9M Q4 '23: -52.9M Q1 '24: -60.7M Q2 '24: -45.8M Q3 '24: -44.6M Q4 '24: -191.9M Q1 '25: -52.2M Q2 '25: -42.7M Q3 '25: -38.8M Q4 '25: -140.7M Q1 '26: -24.2M Q2 '26: -44.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-60M -40M -20M 0 20M 40M 60M Q3 '21: -25.5M Q4 '21: -33.2M Q1 '22: -47.9M Q2 '22: -44.3M Q3 '22: -37.1M Q4 '22: -40.3M Q1 '23: -46.2M Q2 '23: -39.2M Q3 '23: -37.7M Q4 '23: -40.6M Q1 '24: -42M Q2 '24: -38.1M Q3 '24: -35M Q4 '24: -47.2M Q1 '25: -54.7M Q2 '25: -34.5M Q3 '25: -28.6M Q4 '25: -32.3M Q1 '26: -38.5M Q2 '26: -33.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-60M -40M -20M 0 20M 40M 60M Q3 '21: -37.1M Q4 '21: -43.5M Q1 '22: -57.6M Q2 '22: -51.5M Q3 '22: -39.9M Q4 '22: -44.8M Q1 '23: -47.7M Q2 '23: -40.1M Q3 '23: -37.9M Q4 '23: -40.7M Q1 '24: -42M Q2 '24: -38.4M Q3 '24: -35.1M Q4 '24: -47.3M Q1 '25: -55M Q2 '25: -34.6M Q3 '25: -28.6M Q4 '25: -32.6M Q1 '26: -38.6M Q2 '26: -34.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 90M 180M 270M Q1 '21: 17.3M Q2 '21: 42.7M Q3 '21: 239.4M Q1 '22: 244.2M Q2 '22: 246.3M Q3 '22: 248.3M Q1 '23: 249.6M Q2 '23: 250.2M Q3 '23: 251.3M Q1 '24: 254.3M Q2 '24: 12.8M Q3 '24: 12.8M Q1 '25: 14.8M Q2 '25: 14.8M Q3 '25: 18.3M Q1 '26: 21.9M Q2 '26: 23.4M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-27.00 -18.00 -9.00 0.00 9.00 18.00 27.00 Q4 '21: -1.84 Q1 '22: 1.07 Q2 '22: 2.39 Q3 '22: 2.31 Q4 '22: -0.74 Q1 '23: -0.73 Q2 '23: -0.84 Q3 '23: -0.76 Q4 '23: -18.70 Q1 '24: -18.67 Q2 '24: -22.00 Q3 '24: -25.28 Q4 '24: -21.71 Q1 '25: -25.01 Q2 '25: -24.31 Q3 '25: -22.96 Q4 '25: -16.24 Q1 '26: -13.80 Q2 '26: -12.83 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

Not drawn for LYEL: Gross Profit, Cost of Revenue. Nothing in this filer's XBRL supports them for the periods asked for. That is a gap in the filing, not a zero, and drawing a flat line would be an invention.